Search company, investor...
TrialSpark company logo


Founded Year



Series C | Alive

Total Raised




Last Raised

$156M | 2 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+40 points in the past 30 days

About TrialSpark

TrialSpark is a clinical trial management software and drug development company. The company aims to accelerate the pace of clinical trials and bring down costs with a software platform that helps sites like hospitals manage trials and collect and analyze data. Per the company, it uses data from social media to find doctors and patients to participate. While it began as a clinical trial technology platform, in 2021, it signaled a move to using its technology for drug development through the acquisition of biologic and small-molecule drugs. TrialSpark began primarily as a technology company that aims to bring treatments to patients faster using technology that improves clinical trials and drug development. TrialSpark has scaled a network of trial sites by partnering with doctors to create clinical trial sites within their existing practices. TrialSpark runs trials out of these doctor practices using a roaming cohort of certified research coordinators, optimized by software, data, and technology. Without variability in operations at the trial site level, TrialSpark cuts out the manual, time-intensive, and costly tasks that delay clinical trial timelines. By creating trial sites with doctors, TrialSpark unlocks the 98 percent of patients who have never been exposed to trials, boosting recruitment and enrollment rates and democratizing access.

Headquarters Location

16 E 34th Street Floor 10

New York, New York, 10016,

United States


Missing: TrialSpark's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

ESPs containing TrialSpark

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare & Life Sciences / Drug R&D Tech

The clinical study & protocol design market focuses on designing and planning clinical trials and research studies in the field of healthcare and medicine. This market offers a range of solutions and expertise to develop robust study protocols that adhere to ethical guidelines, regulatory requirements, and scientific rigor. By engaging in the clinical study & protocol design market, organizations …

TrialSpark named as Leader among 11 other companies, including Healx, Saama Technologies, and Faro.

Missing: TrialSpark's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing TrialSpark

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TrialSpark is included in 5 Expert Collections, including Unicorns- Billion Dollar Startups.


Unicorns- Billion Dollar Startups

1,214 items


Clinical Trials Tech

341 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.


Digital Health

10,341 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.


Clinical Trials Tech Market Map

108 items

This CB Insights Tech Market Map highlights 100+ clinical trials tech companies that are addressing 8 distinct technology priorities that pharmaceutical companies and CROs face.


Biopharma Tech

326 items

Latest TrialSpark News

Patients see atopic dermatitis improvement with switch from dupilumab to upadacitinib

May 31, 2023

Disclosures: Blauvelt reports being a speaker, advisor or investigator for AbbVie, Abcentra, Acelyrin, Affibody, Aligos, Almirall, Alumis, AnaptysBio, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Concert, Dermavant, EcoR1, Eli Lilly, Escient, EVELO, Evommune, Forte, Galderma, Highlightll Pharma, Incyte, Innovent Bio, Janssen, Landos, LEO Pharma, Merck, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, TLL Pharmaceutical, TrialSpark, UCB, Vibliome and Xencor. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio Patients with continuous upadacitinib maintained EASI improvements. The percentage of patients that switched to upadacitinib from dupilumab and achieved EASI 90 increased from 66.4% to 87.8% after 4 weeks. Patients with moderate to severe atopic dermatitis that switched from dupilumab to upadacitinib experienced significant improvement in efficacy and itch as early as week 4 of treatment, according to a study. “Dupilumab was the first biologic approved to treat [atopic dermatitis (AD)]; however, after 16 weeks of treatment, fewer than 40% of patients achieve clear or almost clear skin and maximal response is not observed until after week 12,” Andrew Blauvelt, MD, MBA, investigator at the Oregon Medical Research Center, and colleagues wrote. Patients with moderate to severe atopic dermatitis that switched from dupilumab to upadacitinib experienced significant improvement in efficacy and itch as early as week 4 of treatment. While dupilumab is still regarded as a highly effective biologic in this indication, according to the study, there are other treatment options available such as upadacitinib, an oral, selective Janus kinase inhibitor that is also approved to treat adolescents and adults with moderate to severe AD . In this 16-week interim analysis of a 52-week open label extension (OLE) study of 484 adults with moderate to severe AD who completed the phase 3b Heads Up trial, researchers evaluated the long-term safety and efficacy of continuous upadacitinib at 30 mg and of switching to upadacitinib after 24 weeks of dupilumab. After 24 weeks of receiving once-daily upadacitinib 30 mg, 239 patients continued the same dosage. Additionally, 245 patients switched from subcutaneous dupilumab 300 mg every other week to once-daily upadacitinib 30 mg at week 22. According to the study, patients on upadacitinib saw a baseline EASI score of 30.5 improve to 2.4 at week 24. Those who continued on the drug maintained this improvement with a score of 2.7 at week 16 of the OLE, and 91% of these patients reported an EASI score of 7 or less at the same time point. Additionally, researchers found that 73.6% of patients receiving continuous upadacitinib achieved EASI 90 and 54.2% achieved a Worst Pruritus-Numerical Rating Scale (WP-NRS) score of 0 or 1 in the extension analysis. Those patients who switched from dupilumab to upadacitinib in the OLE continued to demonstrate an improvement in EASI, according to the study, with a mean EASI score of 28.8 at baseline, 3.29 at week 24 of Heads Up and 1.09 at the end of the 16-week extension analysis. The proportion of patients that switched treatment and achieved EASI 90 increased from 66.4% at week 24 of Heads Up to 87.7% by the end of the 16-week analysis. This jump in EASI 90 was also seen in these patients within 4 weeks of switching biologics, according to the study. Additionally, the researchers found that the percentage of patients that switched treatments and achieved a WP-NRS of 0 or 1 increased from 33.3% to 66.7% after 4 weeks of treatment. The study reports that the safety profile of upadacitinib through the 16-week analysis was consistent with previously published phase 3 AD studies with no new safety risks. The most common adverse events reported in patients that switched from dupilumab to upadacitinib included acne, worsening AD, blood creatinine phosphokinase increase and nasopharyngitis. One patient in the study died due to bone tuberculosis, and this death was not considered to be related to the study drug, according to the researchers. “Upadacitinib provides greater efficacy compared with dupilumab, has a favorable benefit-risk profile, and patients, regardless of prior dupilumab response status, experienced improved outcomes when switched to upadacitinib,” Blauvelt and colleagues concluded. Read more about

TrialSpark Frequently Asked Questions (FAQ)

  • When was TrialSpark founded?

    TrialSpark was founded in 2014.

  • Where is TrialSpark's headquarters?

    TrialSpark's headquarters is located at 16 E 34th Street, New York.

  • What is TrialSpark's latest funding round?

    TrialSpark's latest funding round is Series C.

  • How much did TrialSpark raise?

    TrialSpark raised a total of $238.3M.

  • Who are the investors of TrialSpark?

    Investors of TrialSpark include Sequoia Capital, Thrive Capital, John Doerr, Sound Ventures, Lachy Groom and 11 more.

  • Who are TrialSpark's competitors?

    Competitors of TrialSpark include Inato and 8 more.

Compare TrialSpark to Competitors

Castor EDC

Castor EDC is a medical research data platform. It provides a decentralized clinical trial (DCT) solutions to control clinical trial design. It analyzes, manages, and organizes medical data collected from multiple electronic records. the company was founded in 2011 and is based in New York, New York.

Reify Health Logo
Reify Health

Reify Health provides cloud-based software that accelerates the development of new and life-saving therapies. Reify Health aims to change how clinical trials are run through its StudyTeam and Care Access platforms. StudyTeam delivers a technology platform for optimizing patient recruitment and enrollment. Care Access, which conducts decentralized trials at scale, is a decentralized research organization that aims to bring clinical trial infrastructure directly to patients, healthcare providers, and communities. Reify Health was founded in 2012 and is based in Boston, Massachusetts.

Medable Logo

Medable operates as a global platform for decentralized clinical trials. It solves the systemic challenges inherent in modern clinical trials including access, interoperability between systems, and inefficient technology experiences. It was formerly known as Dermatrap. It was founded in 2012 and is based in Palo Alto, California.


Bloqcube develops cloud-based software enabling distributed and remote clinical trials with storage and real-time reporting of clinical data. It focuses on accelerating clinical trials using modern technology and built integrated clinical trials management and finance systems that enable life science companies to automate trials, monitor in real-time, and deliver immutable data, and more. The company was founded in 2017 and is based in Piscataway, New Jersey.

Curebase Logo

Curebase provides decentralized clinical research software solutions. It reduces recruitment times, automates manual steps, and lets drug companies distribute their trials to clinics. It was founded in 2017 and is based in San Francisco, California.

Hawthorne Effect Logo
Hawthorne Effect

Hawthorne Effect uses a technology platform and trained freelance healthcare investigators (dubbed HEROs) to help improve clinical trial data quality by helping to prevent patient withdrawals and improve data collection and patient satisfaction rates.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.